Hello

Your subscription is almost coming to an end. Don’t miss out on the great content on Nation.Africa

Ready to continue your informative journey with us?

Hello

Your premium access has ended, but the best of Nation.Africa is still within reach. Renew now to unlock exclusive stories and in-depth features.

Reclaim your full access. Click below to renew.

*Alex is the first beneficiary of a trial on a new drug that uses precision oncology, which targets the genetic make-up of tumour with the aim of blocking it from multiplying. If successful, the drug will revolutionise cancer treatment globally.

The goal of the study is to find out if the new drug can be used in the treatment for all cancers.